Dazparda (insulin aspart Sanofi) is a medicine used to control blood sugar in patients with diabetes from one year of age.[1] It contains a fast-acting form of insulin aspart, which is absorbed faster than regular insulin and works faster.[1] It begins to lower the blood glucose level 10-20 minutes after injection, the maximum effect is reached between 1 and 3 hours and lasts for 3-5 hours.[1][4][5] It is administered subcutaneously before meals in combination with intermediate- or long-acting insulins.[1][7] Laboratory studies have confirmed a high similarity to NovoRapid in structure, purity and biological activity.[1] A clinical trial in 597 patients showed the same efficacy: mean HbA1c was 8.00% (Dazparda) and 7.94% (NovoRapid) at baseline, 7.62% and 7.64% after 6 months.[1] The European Medicines Agency (EMA) recognized the equivalence of safety and efficacy with NovoRapid and recommended authorization in the EU.[1]